Abstract: Physical activity provides clinical benefit in Parkinson's disease (PD). Irisin is an exercise-induced polypeptide secreted by skeletal muscle that crosses the blood-brain barrier and mediates certain effects of exercise. Here, we show that irisin prevents pathologic alpha-synuclein (alpha-syn)-induced neurodegeneration in the alpha-syn preformed fibril (PFF) mouse model of sporadic PD. Intravenous delivery of irisin via viral vectors following the stereotaxic intrastriatal injection of alpha-syn PFF cause a reduction in the formation of pathologic alpha-syn and prevented the loss of dopamine neurons and lowering of striatal dopamine. Irisin also substantially reduced the alpha-syn PFF-induced motor deficits as assessed behaviorally by the pole and grip strength test. Recombinant sustained irisin treatment of primary cortical neurons attenuated alpha-syn PFF toxicity by reducing the formation of phosphorylated serine 129 of alpha-syn and neuronal cell death. Tandem mass spectrometry and biochemical analysis revealed that irisin reduced pathologic alpha-syn by enhancing endolysosomal degradation of pathologic alpha-syn. Our findings highlight the potential for therapeutic disease modification of irisin in PD.
Abstract: Despite the extensive knowledge of the beneficial effects of physical exercise, a sedentary lifestyle is still a predominant harm in our society. Sedentarism is one of the major modifiable risk factors for metabolic diseases such as diabetes mellitus, obesity and neurological disorders, including Alzheimer's disease (AD)-characterized by synaptic failure, amyloid protein deposition and memory loss. Physical exercise promotes neuroprotective effects through molecules released in circulation and mediates the physiological crosstalk between the periphery and the brain. This literature review summarizes the current understanding of the roles of exerkines, molecules released during physical exercise, as systemic and central factors that mediate the beneficial effects of physical exercise on cognition. We highlight the neuroprotective role of irisin-a myokine released from the proteolytic cleavage of fibronectin type III domain-containing protein 5 (FNDC5) transmembrane protein. Lastly, we review evidence pointing to physical exercise as a potential preventative and interventional strategy against cognitive decline in AD.
AbstractL Introduction/aims: Becker muscular dystrophy (BMD) is an X-linked disease leading to muscle wasting and weakness. The decrease in lean body mass (LBM) in Duchenne muscular dystrophy, has shown correlation with loss of muscle function and bone density (BD). Myokines (including irisin) are hormones secreted by skeletal muscle that allow crosstalk between muscle and bone. The present study analyzed body composition and circulating myokine levels in a cohort of BMD patients; moreover, the association between dual energy X-ray absorptiometry (DXA) parameters, functional motor assessments, and myokine levels was investigated.
Abstract: Limited data exist regarding the impact of an acute bout of exercise with varying intensities on irisin levels in the youth of different obesity statuses. The objectives were to (1) compare an acute bout of moderate continuous intensity (MCI) exercise and an acute bout of high-intensity interval training (HIIT) on irisin response in youth with different obesity statuses and, (2) investigate whether changes in irisin levels are correlated with exploratory outcomes. A randomized crossover design study was conducted on 25 youth aged 12–18 years old.
The authors used Phoenix's Irisin ELISA Kit (Cat. #EK-067-29) to obtain the plasma level of Irisin/FNDC5 in their research.
Colpitts BH, Rioux BV, Eadie AL, Brunt KR, Sénéchal M. Irisin response to acute moderate intensity exercise and high intensity interval training in youth of different obesity statuses: A randomized crossover trial. Physiological Reports. 2022;10(4).
Catalog# | Product | Standard Size | Price |
---|---|---|---|
EK-067-29 | Irisin, recombinant (Human, Rat, Mouse, Canine) - ELISA Kit | 96 wells | $624 |
EK-067-16 | Irisin (Human, Rat, Mouse, Canine) - EIA Kit | 96 wells | $624 |
067-29 | Irisin, recombinant (Human, Rat, Mouse, Canine) | 10 µg | $136 |
067-29A | Irisin, recombinant (Human, Rat, Mouse, Canine) | 100 µg | $892 |
EK-067-32 | Irisin/FNDC5 (Human, Rat, Mouse, Canine) - EIA Kit | 96 wells | $624 |
067-16 | Irisin (Human, Rat, Mouse, Canine) | 100 µg | $571 |
EK-067-17 | Irisin (42-112) (Human, Rat, Mouse, Canine) - EIA Kit | 96 wells | $624 |
G-067-17 | Irisin (42-112) (Human, Rat, Mouse, Canine) - Purified IgG Antibody | 200 µg | $698 |
067-17 | Irisin (42-112) (Human, Rat, Mouse, Canine) | 100 µg | $444 |
H-067-17 | Irisin (42-112) (Human, Rat, Mouse, Canine) - Antibody | 50 µl | $571 |
Social Network Confirmation